Table 4.
Hazard ratio (HR) and corresponding 95% confidence interval (CI) for HPV-driven tumors vs non-HPV-driven tumors. SPT: second primary tumor
| Survival outcome | Crude estimatesa | Adjusted estimatesb | ||
|---|---|---|---|---|
| HR | (95% CI) | HR | (95% CI) | |
| Mucosal control | 0.10 | (0.02–0.44) | 0.14 | (0.03–0.61) |
| Regional control | 0.18 | (0.05–0.60) | 0.28 | (0.08–1.02) |
| Locoregional control | 0.11 | (0.03–0.36) | 0.16 | (0.05–0.52) |
| Distant control | 0.66 | (0.16–2.67) | 1.64 | (0.31–8.72) |
| SPT controlc | 0.09 | (0.01–0.70) | 0.10 | (0.01–0.83) |
| Progression-free survival | 0.22 | (0.11–0.42) | 0.27 | (0.13–0.54) |
| Overall survival | 0.25 | (0.12–0.49) | 0.33 | (0.16–0.67) |
aAdjusted for gender, age and year of diagnosis. bFurther adjusted for T status, N status, and alcohol drinking. cIncluding only cancer of the head and neck, oesophagus and lung.